Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy Policy7th GA Meeting in Cologne, Germany from 27-29 January 2025!
A huge thank you to everyone for sharing their latest results and project updates! Together we also celebrated exciting progress in our clinical study: MICROB-PREDICT’s ALB-TRIAL has hit a major milestone in January, with 25% of the targeted 240 patients enrolled across nine active centers in Europe, with more sites joining soon!
And of course, we wrapped it up with some after-work fun, exploring Cologne with a ScienceRallye!
Celebrating Milestone for MICROB-PREDICT Project: Terlipressin Study Hits 1,000 Downloads!
We are excited to announce that the groundbreaking research from the MICROB-PREDICT project, "Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis" has surpassed 1,000 full-text views and downloads on Wiley Online Library. This milestone underscores the significant impact of this important study, which highlights the potential risks of terlipressin treatment in patients with advanced liver disease.
We would like to thank the research community and all those who have engaged with this work. The attention it’s received reflects the growing interest in understanding the complex interactions between antimicrobial resistance and cirrhosis care.
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news